Stryker (NYSE:SYK – Get Free Report) had its target price cut by stock analysts at Wells Fargo & Company from $456.00 to $418.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical technology company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 36.64% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. William Blair restated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Evercore set a $390.00 price objective on shares of Stryker in a research report on Monday, January 5th. The Goldman Sachs Group lowered their price objective on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. BTIG Research cut their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Barclays reaffirmed an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research report on Monday, February 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $411.20.
Get Our Latest Stock Report on SYK
Stryker Trading Down 2.9%
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 EPS. Stryker’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts expect that Stryker will post 14.91 earnings per share for the current fiscal year.
Insider Buying and Selling at Stryker
In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Czech National Bank grew its holdings in Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the period. Davis R M Inc. grew its holdings in Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares during the period. Terra Alpha Investments LLC acquired a new stake in Stryker in the third quarter worth $1,216,000. Kepler Cheuvreux Suisse SA acquired a new stake in Stryker in the third quarter worth $27,952,000. Finally, Daymark Wealth Partners LLC grew its holdings in Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after purchasing an additional 37,307 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.
More Stryker News
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker reaffirmed its FY‑2026 outlook (organic sales growth 8%–9.5%; adjusted EPS $14.90–$15.10) and said it is recovering from a recent cyber incident — supports upside if execution continues. Article Title
- Positive Sentiment: Operating cash flow, net income and reported EPS showed strength (cash from operations surged materially year‑over‑year), indicating solid underlying cash generation despite near‑term revenue pressure. Article Title
- Positive Sentiment: Stryker will present at the Bank of America Global Healthcare Conference (May 13), giving management an opportunity to reinforce guidance, address the cyber incident and engage investors. Article Title
- Neutral Sentiment: Wall Street still shows overall positive tilt (several buy/overweight ratings remain and median price target in recent data is elevated), which could limit downside if guidance holds. Article Title
- Neutral Sentiment: Full Q1 press‑conference transcript and earnings call are available for details on segment trends and recovery timelines (useful for investors wanting management commentary). Article Title
- Negative Sentiment: Q1 results missed estimates: adjusted EPS $2.60 vs. consensus around $2.98 and revenue $6.02B vs. ~$6.34B — headline misses are pressuring the share price. Article Title
- Negative Sentiment: Several firms lowered price targets (Needham: $454 → $418; BTIG: $397 → $379; Truist cut its PT), which can weigh on sentiment even when ratings remain “buy.” Article Title Article Title
- Negative Sentiment: Management flagged softer demand in some implant and complex‑procedure categories — cyber incident disruption amplified near‑term demand weakness. Article Title
- Negative Sentiment: Significant insider and institutional selling noted in recent filings/data, which can add pressure to shares if sustained. Article Title
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
